Cargando…
Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial
The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612023/ https://www.ncbi.nlm.nih.gov/pubmed/37896806 http://dx.doi.org/10.3390/v15102029 |
_version_ | 1785128609277542400 |
---|---|
author | Huang, Ying Hejazi, Nima S. Blette, Bryan Carpp, Lindsay N. Benkeser, David Montefiori, David C. McDermott, Adrian B. Fong, Youyi Janes, Holly E. Deng, Weiping Zhou, Honghong Houchens, Christopher R. Martins, Karen Jayashankar, Lakshmi Flach, Britta Lin, Bob C. O’Connell, Sarah McDanal, Charlene Eaton, Amanda Sarzotti-Kelsoe, Marcella Lu, Yiwen Yu, Chenchen Kenny, Avi Carone, Marco Huynh, Chuong Miller, Jacqueline El Sahly, Hana M. Baden, Lindsey R. Jackson, Lisa A. Campbell, Thomas B. Clark, Jesse Andrasik, Michele P. Kublin, James G. Corey, Lawrence Neuzil, Kathleen M. Pajon, Rolando Follmann, Dean Donis, Ruben O. Koup, Richard A. Gilbert, Peter B. |
author_facet | Huang, Ying Hejazi, Nima S. Blette, Bryan Carpp, Lindsay N. Benkeser, David Montefiori, David C. McDermott, Adrian B. Fong, Youyi Janes, Holly E. Deng, Weiping Zhou, Honghong Houchens, Christopher R. Martins, Karen Jayashankar, Lakshmi Flach, Britta Lin, Bob C. O’Connell, Sarah McDanal, Charlene Eaton, Amanda Sarzotti-Kelsoe, Marcella Lu, Yiwen Yu, Chenchen Kenny, Avi Carone, Marco Huynh, Chuong Miller, Jacqueline El Sahly, Hana M. Baden, Lindsey R. Jackson, Lisa A. Campbell, Thomas B. Clark, Jesse Andrasik, Michele P. Kublin, James G. Corey, Lawrence Neuzil, Kathleen M. Pajon, Rolando Follmann, Dean Donis, Ruben O. Koup, Richard A. Gilbert, Peter B. |
author_sort | Huang, Ying |
collection | PubMed |
description | The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution nAb titers were measured at D29 and D57. We assessed these markers as correlates of protection (CoPs) against COVID-19 using stochastic interventional vaccine efficacy (SVE) analysis and principal surrogate (PS) analysis, frameworks not used in our previous COVE immune correlates analyses. By SVE analysis, hypothetical shifts of the D57 Spike IgG distribution from a geometric mean concentration (GMC) of 2737 binding antibody units (BAU)/mL (estimated vaccine efficacy (VE): 92.9% (95% CI: 91.7%, 93.9%)) to 274 BAU/mL or to 27,368 BAU/mL resulted in an overall estimated VE of 84.2% (79.0%, 88.1%) and 97.6% (97.4%, 97.7%), respectively. By binary marker PS analysis of Low and High subgroups (cut-point: 2094 BAU/mL), the ignorance interval (IGI) and estimated uncertainty interval (EUI) for VE were [85%, 90%] and (78%, 93%) for Low compared to [95%, 96%] and (92%, 97%) for High. By continuous marker PS analysis, the IGI and 95% EUI for VE at the 2.5th percentile (519.4 BAU/mL) vs. at the 97.5th percentile (9262.9 BAU/mL) of D57 Spike IgG concentration were [92.6%, 93.4%] and (89.2%, 95.7%) vs. [94.3%, 94.6%] and (89.7%, 97.0%). Results were similar for other D29 and D57 markers. Thus, the SVE and PS analyses additionally support all four markers at both time points as CoPs. |
format | Online Article Text |
id | pubmed-10612023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106120232023-10-29 Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial Huang, Ying Hejazi, Nima S. Blette, Bryan Carpp, Lindsay N. Benkeser, David Montefiori, David C. McDermott, Adrian B. Fong, Youyi Janes, Holly E. Deng, Weiping Zhou, Honghong Houchens, Christopher R. Martins, Karen Jayashankar, Lakshmi Flach, Britta Lin, Bob C. O’Connell, Sarah McDanal, Charlene Eaton, Amanda Sarzotti-Kelsoe, Marcella Lu, Yiwen Yu, Chenchen Kenny, Avi Carone, Marco Huynh, Chuong Miller, Jacqueline El Sahly, Hana M. Baden, Lindsey R. Jackson, Lisa A. Campbell, Thomas B. Clark, Jesse Andrasik, Michele P. Kublin, James G. Corey, Lawrence Neuzil, Kathleen M. Pajon, Rolando Follmann, Dean Donis, Ruben O. Koup, Richard A. Gilbert, Peter B. Viruses Article The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution nAb titers were measured at D29 and D57. We assessed these markers as correlates of protection (CoPs) against COVID-19 using stochastic interventional vaccine efficacy (SVE) analysis and principal surrogate (PS) analysis, frameworks not used in our previous COVE immune correlates analyses. By SVE analysis, hypothetical shifts of the D57 Spike IgG distribution from a geometric mean concentration (GMC) of 2737 binding antibody units (BAU)/mL (estimated vaccine efficacy (VE): 92.9% (95% CI: 91.7%, 93.9%)) to 274 BAU/mL or to 27,368 BAU/mL resulted in an overall estimated VE of 84.2% (79.0%, 88.1%) and 97.6% (97.4%, 97.7%), respectively. By binary marker PS analysis of Low and High subgroups (cut-point: 2094 BAU/mL), the ignorance interval (IGI) and estimated uncertainty interval (EUI) for VE were [85%, 90%] and (78%, 93%) for Low compared to [95%, 96%] and (92%, 97%) for High. By continuous marker PS analysis, the IGI and 95% EUI for VE at the 2.5th percentile (519.4 BAU/mL) vs. at the 97.5th percentile (9262.9 BAU/mL) of D57 Spike IgG concentration were [92.6%, 93.4%] and (89.2%, 95.7%) vs. [94.3%, 94.6%] and (89.7%, 97.0%). Results were similar for other D29 and D57 markers. Thus, the SVE and PS analyses additionally support all four markers at both time points as CoPs. MDPI 2023-09-29 /pmc/articles/PMC10612023/ /pubmed/37896806 http://dx.doi.org/10.3390/v15102029 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Ying Hejazi, Nima S. Blette, Bryan Carpp, Lindsay N. Benkeser, David Montefiori, David C. McDermott, Adrian B. Fong, Youyi Janes, Holly E. Deng, Weiping Zhou, Honghong Houchens, Christopher R. Martins, Karen Jayashankar, Lakshmi Flach, Britta Lin, Bob C. O’Connell, Sarah McDanal, Charlene Eaton, Amanda Sarzotti-Kelsoe, Marcella Lu, Yiwen Yu, Chenchen Kenny, Avi Carone, Marco Huynh, Chuong Miller, Jacqueline El Sahly, Hana M. Baden, Lindsey R. Jackson, Lisa A. Campbell, Thomas B. Clark, Jesse Andrasik, Michele P. Kublin, James G. Corey, Lawrence Neuzil, Kathleen M. Pajon, Rolando Follmann, Dean Donis, Ruben O. Koup, Richard A. Gilbert, Peter B. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial |
title | Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial |
title_full | Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial |
title_fullStr | Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial |
title_full_unstemmed | Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial |
title_short | Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial |
title_sort | stochastic interventional vaccine efficacy and principal surrogate analyses of antibody markers as correlates of protection against symptomatic covid-19 in the cove mrna-1273 trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10612023/ https://www.ncbi.nlm.nih.gov/pubmed/37896806 http://dx.doi.org/10.3390/v15102029 |
work_keys_str_mv | AT huangying stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT hejazinimas stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT blettebryan stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT carpplindsayn stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT benkeserdavid stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT montefioridavidc stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT mcdermottadrianb stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT fongyouyi stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT janeshollye stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT dengweiping stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT zhouhonghong stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT houchenschristopherr stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT martinskaren stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT jayashankarlakshmi stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT flachbritta stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT linbobc stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT oconnellsarah stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT mcdanalcharlene stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT eatonamanda stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT sarzottikelsoemarcella stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT luyiwen stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT yuchenchen stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT kennyavi stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT caronemarco stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT huynhchuong stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT millerjacqueline stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT elsahlyhanam stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT badenlindseyr stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT jacksonlisaa stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT campbellthomasb stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT clarkjesse stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT andrasikmichelep stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT kublinjamesg stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT coreylawrence stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT neuzilkathleenm stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT pajonrolando stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT follmanndean stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT donisrubeno stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT koupricharda stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT gilbertpeterb stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial AT stochasticinterventionalvaccineefficacyandprincipalsurrogateanalysesofantibodymarkersascorrelatesofprotectionagainstsymptomaticcovid19inthecovemrna1273trial |